Population-specific factors associated with fractional excretion of uric acid

Ravi K. Narang 1, Zoe Vincent 1, Amanda Phipps-Green 2, Lisa K. Stamp 3, Tony R. Merriman 2 and Nicola Dalbeth 1*

Abstract

Background: Reduced renal clearance of uric acid is a major contributor to hyperuricemia. The aim of this study was to examine clinical and genetic variables associated with fractional excretion of uric acid (FEUA).

Methods: Participants (with and without gout) in the Genetics of Gout in Aotearoa study with available genotyping and FEUA data were included (n = 1713). Ten FEUA-associated loci detected within a genome-wide association study for serum urate in a European population were analysed. A polygenic score for FEUA was calculated in each ancestry group to model the cumulative effects of the genetic variants on FEUA. Associations between FEUA and both clinical variables and polygenic score were tested using linear regression models.

Results: The mean (SD) FEUA was 5.13 (2.70) % in Eastern Polynesian participants, 4.70 (5.89) % in Western Polynesian participants, and 5.89 (2.73) % in New Zealand European participants. Although association with FEUA was observed for SLC2A9 rs11942223 in New Zealand European participants (P = 2.39 × 10^{-8}), this association was not observed in Eastern or Western Polynesian participants. The polygenic score was positively associated with FEUA in all ancestry groups. In New Zealand European participants, body mass index, diuretic use, polygenic score, and male sex were associated with FEUA and explained 22% of FEUA variance in the regression model. In Eastern and Western Polynesian participants, the tested variables explained 10% and 4% of FEUA variance respectively.

Conclusions: Both clinical and genetic variables contribute to renal clearance of uric acid. SLC2A9 exerts effects on FEUA variance in people of European ancestry, but not in those of Polynesian ancestry. There is a large unexplained variance in FEUA, particularly in people of Polynesian ancestry.

Keywords: Gout, Urate, Uric acid, FEUA, Genetics

Background

Renal under-excretion of uric acid is the dominant cause of hyperuricaemia in 80–90% of people with gout [1, 2]. A number of clinical variables associate with the renal handling of uric acid, including body mass index (BMI) [3], kidney disease [4] and diuretic use [5]. These variables are also important contributors to the development of hyperuricaemia and gout.

Genetic variables also contribute strongly to renal uric acid excretion. Heritability for the fractional excretion of uric acid (FEUA) is estimated to be 46–96% [6–8]. In the Global Urate Genetics Consortium genome-wide association study (GWAS) for serum urate, Köttgen et al. [9] identified ten serum urate-associated single nucleotide polymorphisms (SNPs) that also associated with FEUA in a European sample. For all ten SNPs, the urate-raising allele was associated with a lower FEUA. Other SNPs have been identified that associate with serum urate and gout, and many of these SNPs encode transporters involved in renal uric acid excretion [9–13]. Genetic variants of these transporters can therefore potentially alter FEUA.

Population-specific differences in FEUA also exist and may contribute to differences in gout prevalence. In Aotearoa/New Zealand, there is a high prevalence of gout among Māori (indigenous New Zealanders) and Pacific peoples with 13.3% and 21.9% of men affected respectively, compared to 6.8% of non-Māori, non-Pacific men [14]. Renal under-excretion of uric acid contributes to hyperuricaemia in Māori and Pacific peoples [15, 16], and recent short-term intervention studies have shown...
that Māori and Pacific peoples have low FEUA responses to sugar-sweetened beverage [17] and frusemide challenges [18].

Currently, it is unclear which factors contribute the most to renal handling of uric acid and whether there are population-specific differences in the contribution of these factors. The aim of this study was to examine clinical and genetic factors associated with FEUA in an Aotearoa/New Zealand population.

Methods
Participants
Participants in the Genetics of Gout in Aotearoa study with available genotyping and FEUA data were included in this analysis. The study has been described in detail previously [12]. Study recruitment is ongoing and commenced in 2006. Participants were recruited from the Auckland, Waikato, Canterbury and Otago regions of Aotearoa/New Zealand. The analysis included participants with and without gout, defined by the 1977 American Rheumatism Association criteria for gout [19]. All participants completed a standardised study visit which included clinical assessment and collection of blood and urine for testing.

FEUA was calculated as ([urine urate × serum creatinine] / [serum urate × urine creatinine]) × 100. Urine analysis was performed on spot urine samples. Measurement of FEUA using spot urine samples has been previously demonstrated to be valid and reliable when compared to measurement of FEUA using 24-h urine samples [2]. Participants with a serum creatinine > 300 μmol/L (n = 12), or who were taking the uricosuric agents, probenecid (n = 44) or benzbromarone (n = 2), were excluded from the analysis. Participants taking febuxostat (n = 1) were also excluded from the analysis, as febuxostat use is reported to reduce FEUA [20]. Participants on allopurinol were not excluded, as allopurinol use does not alter FEUA [2, 20]. Participants were analysed according to self-reported ancestry: Eastern Polynesian (Māori and Cook Island), Western Polynesian (Samoa, Tonga, Niue, Tokelau, Tuvalu, Pukapuka), and New Zealand European. Māori and Pacific peoples were also analysed according to self-reported ethnicity, as recommended by the New Zealand Ministry of Health ethnicity reporting protocols [21]. In the case of multiple Polynesian ancestry including Māori (n = 36), participants were analysed as Eastern Polynesian or Māori. Ethical approval was granted by the New Zealand Multi-Region Ethics Committee (MEC/105/10/130) and all participants provided informed written consent.

Single nucleotide polymorphism selection and genotyping
The ten SNPs associated with FEUA identified by Köttgen et al. [9] were genotyped using a combination of Taqman SNP genotyping on a Roche LightCycler 480 and the Sequenom MassARRAY System, as previously described in [12], and a CoreExome array (Illumina). At SLC22A12/NRXN2, SNP rs3825018 (surrogate for rs505802 [10]) was genotyped, and the previously reported rs11942223 was genotyped at SLC2A9. At SLC22A11 (rs2078267), the opposite strand to the allele reported by Köttgen et al. [9] was genotyped using Sequenom/Taqman. Four SNPs were genotyped using both Sequenom/Taqman and a CoreExome Gene-Chip methods (ABCG2 rs2231142, SLC2A11 rs2078267, RREB1 rs675209 and UBE2Q2 rs1394125). There was a > 99% concordance in genotype for each SNP, and as such, any overlapping genotypes were combined. GCKR rs1260326 was genotyped using the CoreExome array alone. The remaining SNPs were genotyped using Sequenom/Taqman alone. The effect allele for each SNP associated with FEUA was defined by Köttgen et al. [9].

Polygenic score
For each ancestry and ethnicity group, a weighted polygenic score for FEUA was calculated to model the cumulative effects of the genetic variants on FEUA. Genetic variants for HLF, NFAT5 and IGFR1 were not included in polygenic score modelling due to a high proportion of missing genotyping data for these loci. For each of the FEUA-associated SNPs, effect sizes (β) for FEUA association within each ancestry and ethnicity group from this analysis were used for polygenic score modelling. For each individual, these effect sizes were multiplied by the number of effect alleles present and summed into a weighted polygenic score for FEUA. A higher polygenic score indicates a greater genetic predisposition for a higher FEUA.

Study power
Power calculations were performed using Quanto (version 1.2.4, May 2009, University of Southern California). Power calculations were performed a priori for the four loci encoding urate transporters (ABCG2 [encoding ABCG2], SLC22A11 [encoding OAT4], SLC22A12 [encoding URAT1], and SLC2A9 [encoding GLUT9]). The power to detect association with FEUA was determined at P < 0.005 significance for a range of presumed effect sizes (0.2–1.0%). For Eastern Polynesian participants, power to detect an association with FEUA was > 80% for SLC22A11 at an effect size of 1.0%, and for SLC22A12 and SLC2A9 at an effect size ≥ 0.8% (Additional file 1: Table S1). For Western Polynesian participants, power to detect an association with FEUA was > 80% for ABCG2 and SLC22A12 at an effect size ≥ 1.0%. For New Zealand European participants, power was > 80% for all four SNPs at an effect size ≥ 0.6% (Additional file 1: Table S1). Power calculations for participants analysed
according to self-reported ethnicity are shown in Additional file 1: Table S2.

We also performed post hoc power calculations for all ten FEUA-associated SNPs at $P < 0.005$ significance using association data generated from this analysis (Additional file 1: Tables S3 and S4). Power to detect association with FEUA at $> 80\%$ was only present for $SLC2A9$ in New Zealand Europeans.

**Statistical analysis**

Data were analysed using IBM SPSS Statistics 25. Clinical characteristics were summarised using standard descriptive statistics including means, standard deviations (SD), number and percent. Association of FEUA with categorical clinical variables (sex, BMI categories, current alcohol intake, diuretic use and estimated glomerular filtration (eGFR) categories) and continuous clinical variables (age, serum triglyceride, serum low-density lipoprotein-cholesterol (LDL-C)) were tested in a linear regression model with FEUA as the dependent outcome. For the linear regression analysis, serum triglyceride was log-transformed due to a right-skewed distribution in all ancestry groups. Linear regression of the ten SNPs (according to the number of effect alleles) with FEUA as the dependent variable was performed with adjustment for age and sex. Association of the polygenic score with FEUA was also tested using linear regression. All clinical variables and the polygenic score were entered into a linear regression model with FEUA as the dependent variable. The adjusted $R$-square was used to estimate the proportion of the variance in FEUA explained by the model. In the analysis for Eastern Polynesian, Western Polynesian, Māori and Pacific participants, the linear regression analysis was also adjusted for a measure of Polynesian ancestry, based on the number of Polynesian grandparents. Variables associated with FEUA were also tested for their association with individual components of the FEUA calculation (serum urate, serum creatinine and urinary urate/urinary creatinine) in a univariate linear regression analysis and a multivariable linear regression analysis including all clinical variables and the polygenic score. Data from regression analyses were summarised using unstandardised $\beta$ coefficients and standardised $\beta$ coefficients. The standardised $\beta$ coefficient refers to the number of standard deviations the dependent outcome would change, per standard deviation increase in the tested variable. Where multiple testing was used in the SNP analysis, experiment-wide significance was defined as $P < 0.005$.

**Results**

**Clinical features of study participants**

The clinical characteristics are shown in Table 1. There were 1713 participants in total. There were 483 (28.2%) Eastern Polynesian participants, 282 (16.5%) Western Polynesian participants and 948 (55.3%) New Zealand European participants.

The frequency distribution of FEUA in the entire study population and according to ancestry group is shown in Additional file 1: Figure S1. The mean (SD) FEUA of the entire study population was 5.48 (2.71) %. The mean (SD) FEUA was 5.13 (2.70) % in Eastern Polynesian participants, 4.70 (5.89) % in Western Polynesian participants and 5.89 (2.73) % in New Zealand European participants (ANOVA $P = 2.10 \times 10^{-12}$). There was no significant difference in FEUA between Eastern and Western Polynesian participants (Tukey post hoc $P = 0.08$). FEUA was significantly lower in Eastern and Western Polynesian participants, compared to New Zealand European participants (Tukey post hoc $P = 1.18 \times 10^{-6}$ and $P = 5.30 \times 10^{-9}$ respectively).

**Association of FEUA with clinical variables in linear regression analysis**

In the linear regression analysis, male sex, BMI $\geq 30$ kg/m$^2$, and diuretic use were inversely associated with FEUA in Eastern Polynesian and New Zealand European participants (Table 2). In Western Polynesian participants, only male sex was inversely associated with FEUA; however, inverse association of BMI $\geq 30$ kg/m$^2$ and diuretic use with FEUA was approaching statistical significance ($P = 0.07$ and $P = 0.06$ respectively). The remaining clinical variables (current alcohol intake, eGFR $< 60$ ml/min, age, serum LDL-C, and serum triglyceride) were not associated with FEUA in any ancestry group (Table 2).

**Association of FEUA with genetic variables**

Genotype distribution, call rate, and Hardy-Weinberg equilibrium data are shown in Additional file 1: Table S5. In the Polynesian ancestry groups, no association between $SLC2A9$ and FEUA was observed (Table 3). In Eastern Polynesian participants, all had at least one $SLC2A9$ effect allele, and in Western Polynesian participants, only one participant did not carry the effect allele (Additional file 1: Table S5). Furthermore, no other SNPs met experiment-wide significance for association with FEUA in any Polynesian ancestry group. In contrast, in New Zealand European participants, association with FEUA was observed at experiment-wide significance for $SLC2A9$ (standardised $\beta = -0.17$, $P = 2.39 \times 10^{-8}$), (Table 3). There were 915 (96.8%) New Zealand European participants with genotyping data for $SLC2A9$ who had at least one $SLC2A9$ effect allele (Additional file 1: Table S5).

Association for FEUA at nominal significance ($P < 0.05$) was observed for $SLC22A11$ and $SLC2A9$ in Eastern Polynesian participants, $HLF$ in Western Polynesian
participants, and GCKR in New Zealand European participants (Table 3). Genotype distribution, call rate, and Hardy-Weinberg equilibrium data for participants analysed according to self-reported ethnicity are shown in Additional file 1: Table S6; no SNPs met experiment-wide significance for association with FEUA in this analysis (Additional file 1: Table S7).

A higher polygenic score was associated with a higher FEUA in all ancestry groups in the univariate analysis (Table 4). In a repeat analysis that excluded SLC2A9 from the polygenic score modelling, a higher polygenic score was still associated with a higher FEUA in Eastern Polynesian and New Zealand European participants, with a similar trend observed in Western Polynesian participants. For Western Polynesian participants, only the polygenic score was an independent predictor of FEUA, explaining 4% of FEUA variance (Table 5). In Western Polynesian participants, effect sizes for BMI ≥ 30 kg/m² (standardised $\beta = 0.13, P = 0.053$), male sex (standardised $\beta = 0.11, P = 0.08$) and diuretic use (standardised $\beta = 0.12, P = 0.02$).

### Association of FEUA with clinical and genetic variables in linear regression analysis

In both Eastern Polynesian participants and New Zealand European participants, BMI ≥ 30 kg/m², diuretic use, male sex, and polygenic score were independent predictors of FEUA (Table 5). These four variables explained 10% of the FEUA variance in Eastern Polynesian participants, and 22% in New Zealand European participants. For Western Polynesian participants, only the polygenic score was an independent predictor of FEUA, explaining 4% of FEUA variance (Table 5). In Western Polynesian participants, effect sizes for BMI ≥ 30 kg/m² (standardised $\beta = 0.13, P = 0.053$), male sex (standardised $\beta = 0.11, P = 0.08$) and diuretic use (standardised $\beta =$ 0.12, $P = 0.02$).

### Table 1 Clinical characteristics of the study participants

|                      | All $n = 1713$ | Eastern Polynesian $n = 483$ | Western Polynesian $n = 282$ | New Zealand European $n = 948$ |
|----------------------|---------------|-----------------------------|-----------------------------|---------------------------------|
| Age, mean (SD), years| 54.1 (17.5)   | 50.0 (17.1)                 | 43.7 (16.5)                 | 59.4 (15.9)                     |
| Male sex, n (%)      | 1227 (71.6)   | 286 (59.2)                  | 179 (63.5)                  | 762 (80.4)                      |
| BMI, mean (SD), kg/m²| 30.8 (6.8)    | 326 (7.7)                   | 340 (6.5)                   | 289 (5.7)                       |
| < 25 kg/m², n (%)    | 325 (19.0)    | 65 (13.5)                   | 22 (7.8)                    | 238 (25.1)                      |
| ≥ 25 kg/m² and < 30 kg/m², n (%) | 549 (32.0) | 122 (25.3)                  | 50 (17.7)                   | 377 (39.8)                      |
| ≥ 30 kg/m², n (%)    | 839 (49.0)    | 296 (61.3)                  | 210 (74.5)                  | 333 (35.1)                      |
| Current alcohol intake, n (%) | 1002 (58.5) | 208 (43.1%)                 | 101 (35.8)                  | 693 (73.1)                      |
| Gout, n (%)          | 896 (52.3)    | 206 (42.7)                  | 124 (44.0)                  | 566 (59.7)                      |
| Allopurinol use, n (%) | 709 (41.4)  | 170 (35.2)                  | 109 (38.7)                  | 430 (45.4)                      |
| Diuretic use, n (%)  | 322 (18.8)    | 93 (19.3)                   | 38 (13.5)                   | 191 (20.1)                      |
| Serum creatinine, mean (SD), μmol/L | 101.1 (32.7) | 95.9 (29.1)                | 100.9 (33.5)                | 103.7 (33.9)                     |
| eGFR ≥ 60 ml/min/1.73 m², n (%) | 1274 (74.4) | 380 (78.8)                  | 213 (76.6)                  | 657 (71.4)                      |
| Serum urate, mean (SD), mmol/L | 0.39 (0.11)  | 0.38 (0.10)                 | 0.41 (0.11)                 | 0.38 (0.10)                      |
| Serum LDL-C, mean (SD), mmol/L | 2.84 (0.96) | 2.82 (0.96)                 | 2.8 (0.92)                  | 2.88 (0.97)                      |
| Serum triglyceride, mean (SD), mmol/L | 2.06 (1.43) | 2.12 (1.44)                 | 1.97 (1.31)                 | 2.06 (1.45)                      |
| FEUA, mean (SD), %   | 5.48 (2.71)   | 5.13 (2.70)                 | 4.70 (5.89)                 | 5.89 (2.73)                      |

BMI body mass index, eGFR estimated glomerular filtration rate, FEUA fractional excretion of uric acid, LDL-C low-density lipoprotein-cholesterol, SD standard deviation.

### Table 2 Linear regression analysis of clinical variables with fractional excretion of uric acid

|                      | Eastern Polynesian $n = 483$ | Western Polynesian $n = 282$ | New Zealand European $n = 948$ |
|----------------------|-----------------------------|-----------------------------|---------------------------------|
| Male sex             | $-0.52$ (0.25) $-0.10$ 0.04 | $-0.67$ (0.32) $-0.13$ 0.04 | $-1.72$ (0.22) $-0.25$ 4.73 $\times 10^{-15}$ |
| BMI ≥ 30 kg/m²        | $-0.78$ (0.18) $-0.21$ 2.16 $\times 10^{-5}$ | $-0.49$ (0.27) $0.12$ 0.07 | $-0.82$ (0.12) $-0.23$ 4.77 $\times 10^{-12}$ |
| Current alcohol intake | 0.35 (0.25) 0.06 0.17 | $-0.37$ (0.31) $-0.07$ 0.23 | $-0.35$ (0.20) $-0.06$ 0.08 |
| Diuretic use         | $-0.85$ (0.34) $-0.12$ 0.01 | $-1.01$ (0.54) $-0.14$ 0.06 | $-0.87$ (0.23) $-0.13$ 2.11 $\times 10^{-4}$ |
| eGFR < 60 ml/min     | $-0.03$ (0.34) $-4.05$ $\times 10^{-5}$ 0.94 | $-0.25$ (0.44) $-0.04$ 0.57 | 0.36 (0.21) 0.06 0.10 |
| Age                  | $-0.01$ (0.01) $-0.08$ 0.13 | $2.53$ $\times 10^{-3}$ 0.01 $-0.02$ 0.82 | $-0.01$ (0.01) $-0.05$ 0.16 |
| LDL-C                | 0.06 (0.13) 0.02 0.63 | 0.04 (0.17) 0.02 0.81 | 1.66 $\times 10^{-3}$ 0.09 0.00 0.98 |
| Triglyceride         | $-0.03$ (0.15) $-0.01$ 0.83 | $-0.07$ (0.18) $0.03$ 0.70 | $-0.19$ (0.10) $-0.06$ 0.07 |

BMI body mass index, eGFR estimated glomerular filtration rate, LDL-C low-density lipoprotein-cholesterol, SE standard error.
FEUA calculation in the multivariable linear regression analysis was associated with all individual components of the FEUA and polygenic score with individual components of the S8 and S9. For Eastern Polynesian participants, male sex were independent predictors for FEUA in Māori participants, explaining 11% of FEUA variance (Additional file 1: Table S9). When Polynesian participants were analysed according to ethnicity, BMI $\geq 30$ kg/m$^2$, polygenic score and male sex were independent predictors for FEUA in Māori participants, explaining 11% of FEUA variance (Additional file 1: Table S9). For Pacific peoples, BMI $\geq 30$ kg/m$^2$, diuretic use and polygenic score were associated or approaching statistical significance for association with all ancestry groups (data not shown).

Table 3 Linear regression analysis of 10 single nucleotide polymorphisms with fractional excretion of uric acid

| Gene SNP       | Eastern Polynesian n = 483 | Western Polynesian n = 282 | New Zealand European n = 948 |
|----------------|-----------------------------|-----------------------------|-------------------------------|
|                | Effect allele freq | $\beta$ | SE $\beta$ | Stan. $\beta$ | $P$ | Effect allele freq | $\beta$ | SE $\beta$ | Stan. $\beta$ | $P$ | Effect allele freq | $\beta$ | SE $\beta$ | Stan. $\beta$ | $P$ |
| ABCG2 rs2231142| 0.102 | 0.48 | 0.29 | 0.07 | 0.10 | 0.302 | $\beta$ | 0.25 | 0.21 | 0.07 | 0.24 | 0.195 | $\beta$ | 0.06 | 0.15 | 0.01 | 0.70 |
| GCKR rs1260326 | 0.341 | $-0.22$ | 0.18 | $-0.05$ | 0.24 | 0.266 | $\beta$ | 0.05 | 0.22 | 0.01 | 0.82 | 0.430 | $\beta$ | $-0.28$ | 0.13 | $-0.07$ | 0.03 |
| HLF rs7224610  | 0.192 | 0.34 | 0.13 | 0.11 | 0.09 | 0.164 | $\beta$ | 0.44 | 0.13 | 0.11 | 0.01 | 0.429 | $\beta$ | 0.21 | 0.19 | 0.06 | 0.30 |
| IGF1R rs6598541| 0.798 | $-0.34$ | 0.24 | $-0.08$ | 0.16 | 0.888 | 0.43 | 0.41 | 0.08 | 0.30 | 0.380 | 0.06 | 0.13 | 0.02 | 0.64 |
| NFAT5 rs7193778| 0.119 | $-0.15$ | 0.18 | $-0.03$ | 0.40 | 0.148 | $\beta$ | $-0.15$ | 0.17 | $-0.03$ | 0.40 | 0.835 | $\beta$ | $-0.41$ | 0.25 | $-0.08$ | 0.11 |
| RREB1 rs675209 | 0.727 | $-0.36$ | 0.19 | $-0.09$ | 0.06 | 0.885 | 0.449 $\times 10^{-3}$ | 0.33 | 0.00 | 0.99 | 0.278 | $\beta$ | $-0.09$ | 0.13 | 0.02 | 0.51 |
| SLC22A11 rs2078267| 0.840 | $-0.55$ | 0.23 | $-0.11$ | 0.02 | 0.945 | 0.09 | 0.47 | 0.01 | 0.84 | 0.535 | 0.03 | 0.12 | 0.01 | 0.80 |
| SLC22A12 rs3825018| 0.681 | $-0.21$ | 0.20 | $-0.05$ | 0.28 | 0.710 | 0.07 | 0.26 | 0.02 | 0.79 | 0.296 | $\beta$ | $-0.24$ | 0.13 | $-0.06$ | 0.07 |
| SLC2A9 rs11942223| 0.935 | $-0.80$ | 0.37 | $-0.10$ | 0.03 | 0.966 | 0.86 | 0.57 | 0.09 | 0.13 | 0.827 | $\beta$ | $-0.86$ | 0.15 | $-0.17$ | 2.39 $\times 10^{-8}$ |
| UBE2Q2 rs1394125| 0.162 | $-0.17$ | 0.23 | $-0.03$ | 0.47 | 0.056 | $\beta$ | $-0.21$ | 0.45 | $-0.03$ | 0.63 | 0.623 | $\beta$ | 0.13 | 0.12 | 0.03 | 0.29 |

Data adjusted for age and sex. Freq frequency, SE standard error, SNP single nucleotide polymorphism, Stan. standardised

0.13, $P = 0.07$) were similar to participants of Eastern Polynesian and New Zealand European ancestry and were approaching statistical significance for predictors of FEUA.

The same predictors of FEUA were found in all ancestry groups when BMI and eGFR were entered as continuous variables in the models and when serum creatinine was substituted for eGFR (data not shown). Similarly, when alcohol intake was analysed according to the number of grams of alcohol intake per week, the same predictors for FEUA were found in all ancestry groups (data not shown).

Data for the association of clinical variables and the polygenic score with individual components of the FEUA calculation are shown in Additional file 1: Tables S8 and S9. For Eastern Polynesian participants, male sex was associated with all individual components of the FEUA calculation in the multivariable linear regression analysis. BMI $\geq 30$ kg/m$^2$ was approaching statistical significance for association with serum urate and serum creatinine. Diuretic use was associated with a higher serum urate and serum creatinine, and the FEUA polygenic score was inversely associated with serum urate. In New Zealand European participants, male sex, BMI $\geq 30$ kg/m$^2$, diuretic use and polygenic score were associated or approaching statistical significance for association with all components of the FEUA calculation (Additional file 1: Table S9).

Table 4 Univariate linear regression analysis of polygenic score with fractional excretion of uric acid

| Polygenic score | Eastern Polynesian | Western Polynesian | New Zealand European |
|-----------------|-------------------|-------------------|----------------------|
| $\beta$ | SE $\beta$ | Standardised $\beta$ | $P$ | $\beta$ | SE $\beta$ | Standardised $\beta$ | $P$ | $\beta$ | SE $\beta$ | Standardised $\beta$ | $P$ |
| Including SLC2A9| 11.71 | 2.83 | 0.19 | $4.11 \times 10^{-5}$ | 14.63 | 6.98 | 0.12 | 0.04 | 13.91 | 2.23 | 0.20 | $6.52 \times 10^{-10}$ |
| Not including SLC2A9| 10.69 | 2.92 | 0.16 | $2.78 \times 10^{-4}$ | 15.87 | 8.94 | 0.11 | 0.08 | 11.45 | 3.88 | 0.10 | $3.25 \times 10^{-3}$ |

A higher polygenic score indicates a greater genetic predisposition for a higher FEUA. SE standard error
FEUA and explained 5% of FEUA variance. In this group, polygenic score was approaching statistical significance as a predictor for FEUA (standardised $\beta$ 0.09, $P = 0.07$).

**Discussion**

This study has identified independent clinical and genetic variables that contribute to fractional excretion of uric acid. In people of New Zealand European ancestry, these variables include high body mass index, diuretic use, male sex and polygenic score. There is a large unexplained variance in FEUA, particularly in Polynesian people.

Sex-specific differences in the epidemiology and clinical characteristics of hyperuricaemia and gout are well described. Hyperuricaemia and gout prevalence is higher in men compared to women [22], and it is unusual for pre-menopausal women to present with gout in the absence of other risk factors, such as diuretic use or kidney disease [23, 24]. The uricosuric effect of female sex hormones may explain these differences [25, 26]. In the regression models, male sex was associated with a lower FEUA in Eastern Polynesian and New Zealand European participants and was approaching statistical significance for Western Polynesian participants ($P = 0.08$).

Diuretic use was associated with a lower FEUA in Eastern Polynesian and New Zealand European participants, with a similar trend for Western Polynesian participants. The association of diuretic use with hyperuricaemia [27] and gout [28] is well recognised. Diuretics are thought to affect renal uric acid excretion through their action on renal uric acid transporters. Possible mechanisms include diuretic-uric acid exchange via OAT4 on the basolateral membrane of renal tubular cells [29], and inhibition of urate transporters such as OAT1 and OAT3 on the basolateral membrane [5], and MRP4 and NPT4 on the apical membrane [5, 30]. Diuretics also affect renal uric acid excretion via indirect mechanisms related to intravascular volume contraction and salt loss which stimulates renal solute (including uric acid) reabsorption [31].

A high BMI was associated with a lower FEUA in Eastern Polynesian and New Zealand European participants and was approaching statistical significance for Western Polynesian participants. Although BMI is known to negatively correlate with FEUA, it is currently unclear whether this is a direct effect of BMI itself, or associated mediators (such as high circulating insulin, triglycerides, glucose) [3, 32]. Our group has previously reported no association between FEUA and BMI in a fasting state, but that people with overweight/obesity range BMI have a lower FEUA response after hyperuricaemia induced by a fructose load [33].

Of the genetic loci associated with serum urate, the SLC2A9 variant exerts the greatest effect accounting for approximately 3–4% of inter-individual variance in European people [9]. SLC2A9 encodes GLUT9, a high capacity urate transporter expressed in proximal renal tubular cells and the liver [34]. The SLC2A9 variant is more prevalent in Eastern and Western Polynesian people compared to New Zealand European people and confers a strong risk for gout [35]. In our study, all Eastern Polynesian participants had at least one SLC2A9 effect allele, and in Western Polynesian people, only one participant did not carry the effect allele. This would have eliminated the power to detect associations between FEUA and the SLC2A9 variant in these ancestry groups. Other potential explanations for a lack of association include undiscovered population-specific genetic variants in SLC2A9 and in other genes, differences in clinical factors mediating renal uric acid excretion such as insulin resistance, or other factors (genetic or clinical) interacting with SLC2A9. For example, a Western Polynesian-specific genetic variant in ABCC4 associates with FEUA in men [36]. Despite the lack of association with SLC2A9, the polygenic score was a predictor for FEUA in Eastern Polynesian and Western Polynesian participants. This suggests that despite the lack of

| Table 5 Predictors of fractional excretion of uric acid in linear regression analysis |
|--------------------------------------|-----------------|-----------------|
| Variable                             | Standardised $\beta$ | $P$              |
| Eastern Polynesian                    |                  |                 |
| Body mass index $\geq 30$ kg/m$^2$    | $-0.18$          | $4.58 \times 10^{-4}$ |
| Diuretic use                          | $-0.11$          | 0.03            |
| Male sex                             | $-0.11$          | 0.02            |
| Polygenic score*                     | 0.14             | 0.01            |
| Western Polynesian                    |                  |                 |
| Polygenic score*                     | 0.12             | 0.049           |
| New Zealand European                 |                  |                 |
| Body mass index $\geq 30$ kg/m$^2$    | $-0.21$          | $3.54 \times 10^{-10}$ |
| Diuretic use                          | $-0.12$          | $4.59 \times 10^{-4}$ |
| Male sex                             | $-0.27$          | $3.03 \times 10^{-16}$ |
| Polygenic score*                     | 0.15             | $1.02 \times 10^{-6}$ |

*A higher polygenic score indicates a greater genetic predisposition for a higher FEUA*
experiment-wide association for a single SNP with FEUA, the cumulative effects of multiple serum urate-associated SNPs can still potentially influence FEUA in these ancestry groups.

The lack of association between ABCG2 and FEUA confirms the previous finding of Kannangara et al. [37] and is expected due to overlapping datasets. The finding is also notable as it differs from the results of a larger European analysis which demonstrated a small (non-experiment-wide significant) reduction in FEUA with the urate-raising variant [9]. The lack of association in our study is in keeping with the likely mechanism of hyperuricaemia induced by genetic variants of ABCG2. The ABCG2 transporter functions predominantly as a gut secretory urate transporter with excretion of urate blocked in the presence of the effect allele. This reduced extra-renal urate clearance results in a ‘renal overload’ hyperuricaemia and a relative increase in the daily excretion of urate without a change in FEUA.

An association between GCKR and FEUA was observed in New Zealand Europeans at nominal significance and replicates the findings by Kötting et al. [9]. GCKR influences the hepatic production of glucose-6-phosphate, which is a precursor for de novo purine synthesis. It also associates with triglyceride [38], and the association with serum urate is attenuated by triglyceride levels [39]. It is unclear how the GCKR protein may influence FEUA. It may be that the genetic variant of GCKR influences the levels of a metabolite in the glycolytic pathway that alters renal uric acid excretion.

Our study showed a large unexplained variance in FEUA, particularly in Eastern and Western Polynesian groups. This is despite testing all available clinical variables and the polygenic score in the multivariable linear regression analysis. In the Eastern Polynesian and New Zealand European analysis, the same four variables were found to be predictors for FEUA; however, the overall variance explained was much lower for the Eastern Polynesian group (10% vs 22%). Genetic variants of other loci (that may have population-specific effects) not tested in this analysis may account for some of the unexplained variance. Another explanation is the presence of rare or low-frequency genetic variants associated with serum urate that were not tested in this study. These variants have been shown to exert a larger effect individually on serum urate than the common variants that are mapped into the same loci [40].

This study has a number of strengths and limitations. An important strength is the recruitment of Māori and Pacific peoples, who have a high prevalence of early-onset and severe gout. A further strength was the standardised study visits and methodology. Limitations include the modest sample size for our analysis, particularly for Māori and Pacific participants, which reduced the power to detect associations with FEUA in the Polynesian ancestry groups. Secondly, although our study tested ten FEUA-associated SNPs, it is possible that SNPs associated with serum creatinine may also associate with FEUA and provide a further genetic contribution to the overall FEUA variance. Genotyping data for serum creatinine-associated SNPs were not available for this analysis; however, a positive association between the serum urate-raising SNP of GCKR with eGFR and a negative association between the serum urate-raising SNP of UBE2Q2 with eGFR have been previously reported [41, 42]. Thirdly, as the FEUA-associated genetic variants tested in this study were identified by genome-wide analysis in a European population [9], the influence of these genetic variants cannot be directly generalised to Polynesian ancestry groups. However, we note the consistent pattern of association of the ten variants with gout between European and Polynesian populations [12] (five of the variants were significantly and directionally consistently associated with gout in both Europeans and Polynesians with an average difference in odds ratio of only 0.16), suggesting that some degree of generalisability is possible.

Conclusion

Both clinical and genetic variables contribute to renal clearance of uric acid. SLC2A9 rs11942223 exerts effects on FEUA variance in people of European ancestry, but not in Eastern and Western Polynesian people. There is a large unexplained variance in FEUA, particularly in people of Polynesian ancestry.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s13075-019-2016-6.

Additional file 1: Table S1. Power to detect association between single nucleotide polymorphisms and fractional excretion of uric acid. Table S2. Power to detect association between single nucleotide polymorphisms and fractional excretion of uric acid. Table S3. Power to detect association between single nucleotide polymorphisms and fractional excretion of uric acid. Table S4. Power to detect association between single nucleotide polymorphisms and fractional excretion of uric acid. Table S5. Genotype distribution, call rate, and Hardy-Weinberg equilibrium data for fractional excretion of uric acid-associated single nucleotide polymorphisms. Table S6. Genotype distribution, call rate, and Hardy-Weinberg equilibrium data for fractional excretion of uric acid-associated single nucleotide polymorphisms. Table S7. Association analysis of 10 single nucleotide polymorphisms with fractional excretion of uric acid. Table S8. Univariate linear regression analysis of male sex, body mass index, diuretic use and polygenic score with variables included in fractional excretion of uric acid calculation. Table S9. Multivariable linear regression analysis of male sex, body mass index, diuretic use and polygenic score with variables included in fractional excretion of uric acid calculation. Table S10. Predictors of fractional excretion of uric acid in linear regression analysis. Figure S1. Frequency distribution of fractional excretion of uric acid in all participants and according to ancestry group. FEUA, fractional excretion of uric acid.

Abbreviations

ABCC4: ATP-binding cassette subfamily 4 member 4; ABCG2: ATP-binding cassette subfamily G member 2; ANOVA: Analysis of variance; BMI: Body mass
index; eGFR: Estimated glomerular filtration rate; FEUA: Fractional excretion of uric acid; GCGR: Glucokinase regulator; GWAS: Genome-wide association study; HLF: Hepatic leukaemia factor; LDL-C: Low-density lipoprotein-cholesterol; SD: Standard deviation; SLC17A1: Solute carrier family 17 member 1; SLC22A1: Solute carrier family 2 member 1; SLC22A12: Solute carrier family 2 member 12; SLC22A9: Solute carrier family 2 member 9; SNP: Single nucleotide polymorphism

Acknowledgements
The authors would like to thank Jill Drake, Roddi Laurence, Meaghan House and Gabrielle Sexton for assistance in recruitment.

Authors’ contributions
RN analysed and interpreted the data and drafted the manuscript. ZV and APG contributed to data analysis and interpretation and helped draft the manuscript. ND has received consulting fees, speaker fees or grants from AstraZeneca. ND has received consulting fees, speaker fees or grants from AstraZeneca. ND has received consulting fees, speaker fees or grants from AstraZeneca. ND has received consulting fees, speaker fees or grants from AstraZeneca.

Availability of data and materials
Owing to consent restrictions, the individual-level data used for this study cannot be made publicly available. All data generated or analysed during this study are included in this published article (and its supplementary information files).

Ethics approval and consent to participate
The New Zealand Multi-Region Ethics Committee (MEC/105/10/130) granted ethical approval for the study, and all participants gave written informed consent. Ethics approval and consent to participate were granted by the New Zealand Multi-Region Ethics Committee (MEC/105/10/130). Consent for publication was not applicable.

Competition of interest
TRM has received consulting fees or grants from Ardea Biosciences and AstraZeneca. PF has received consulting fees, speaker fees or grants from AstraZeneca/ironwood, Kowa, Horizon, Amgen, Abbvie, Takeda, Pfizer and Janssen. Other authors declare that they have no competing interests.

Author details
1Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand.
2Department of Biochemistry, University of Otago, 710 Cumberland Street, Dunedin 9012, New Zealand.
3Department of Medicine, University of Otago, 2 Riccarton Avenue, Christchurch 8140, New Zealand.

Received: 13 June 2019 Accepted: 25 September 2019

Published online: 12 November 2019

References
1. Pascual E, Perdigueró M, Gout, diuretics and the kidney. Ann Rheum Dis. 2006;65(8):981–2.
2. Kannangara DRW, Ramasamy SN, Indraratna PL, Stocker SL, Graham GG, Jones G, et al. Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. Arthritis Res Ther. 2012;14(4):R189.
3. Yamashita S, Matsuzawa Y, Tokunaga K, Fujikawa S, Tarui S. Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes. 1986;10(4):355–6.
4. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newmann AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Ann Intern Med. 2007;147(2):239–47.
5. Jutabha P, Anzai N, Wempe MF, Waku S, Endou H, Sakurai H. Apical voltage-driven urate efflux transporter Npt4 in renal proximal tubule. Nucleos Nucleot Nucl. 2011;30(12):1302–11.
6. Emmerson BT, Nagel SL, Duffy DL, Martin NG. Genetic-control of the renal clearance of urate - a study of twins. Ann Rheum Dis. 1992;51(3):375–7.
7. Monga M, Macias B, Groppe E, Hargens A. Genetic heritability of urinary stone risk in identical twins. J Urol. 2006;176(2):6125–8.
8. Nilsson SE, Read S, Berg S, Johansson B. Heritabilities for fifteen routine biochemical values: findings in 215 Swedish twin pairs 82 years of age or older. Scand J Clin Lab Invest. 2009;69(5):562–9.
9. Kottingen A, Albrecht E, Teumer A, Vitart V, Krumdieck J, Hundsdoerfer C, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45(2):145–54.
10. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perala M, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5(9):e1000504.
11. Yang QO, Kottingen A, Dehghann A, Smith AV, Glazer NL, Chen MH, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Gene. 2010;3(6):523–30.
12. Phipps-Green AI, Mertiman ME, Topliss R, Altaf S, Montgomery GW, Franklin C, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis. 2016;75(1):24–30.
13. Dehghann A, Kottingen A, Yang Q, Hwang SJ, Kao WHL, Rivadeneira F, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372(9654):1953–61.
14. Dalbeth N, Dowell T, Gerard C, Gow P, Jackson G, Shuker C, et al. Gout in Aoteaora New Zealand: the equity crisis continues in plain sight. N Z Med J. 2018;131(14858):12.
15. Gibson T, Waterworth R, Hatfield P, Robinson G, Bremner K. Hyperuricaemia, gout and kidney function in New Zealand Maori men. Br J Rheumatol. 1984;23(4):276–82.
16. Simmonds HA, McBride MB, Hatfield PJ, Graham R, McCaskey J, Jackson M. Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling. Br J Rheumatol. 1994;33(10):932–7.
17. Dalbeth N, House ME, Gambale GD, Horne A, Pool B, Purvis L, et al. Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. Ann Rheum Dis. 2013;72(11):1868–73.
18. Dalbeth N, Allan J, Gambale GD, Phipps-Green A, Flynn TJ, Mihov B, et al. Influence of genetic variants on renal uric acid handling in response to furosемide: an acute intervention study. Rind Open. 2017;3(11):e000424.
19. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895–900.
20. Liu S, Perez-Ruz F, Miner JN. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. Joint Bone Spine. 2017;84(2):183–8.
21. Ministry of Health. 2017. HISO 10001:2017 Ethnicity Data Protocols. Wellington: Ministry of Health. https://www.health.govt.nz/publication/hiso-100012017-ethnicity-data-protocols.
22. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricaemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–41.
23. Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65(10):1369–72.
24. Harrold LR, Etzel CJ, Gibofsky A, Kreider JM, Pillinger MH, Saag KG, et al. Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 2017;18(1):108.
25. Nichols A, Snith ML, Scott JT. Effect of estrogen therapy on plasma and urinary levels of uric acid. Brit Med J. 1973;1(5851):449–51.
26. Yahyaoui R, Esteva I, Haro-Mora JJ, Almaraz MC, Morcillo S, Rojo-Martinez G, et al. Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. J Clin Endocrinol Metab. 2008;93(6):2230–3.
27. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the systolic hypertension in the elderly program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158(7):741–51.
28. Choi HK, Soriano LC, Zhang YQ, Rodriguez LAG. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. Brit Med J. 2012;344:d8190.
29. Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol. 2007;18(2):430–9.
30. El-Sheikh AAK, van den Heuvel JJMW, Koenderink JB, Russel FJM. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Brit J Pharmacol. 2008;155(7):1066–75.
31. Kahn AM. Indirect coupling between sodium and urate transport in the proximal tubule. Kidney Int. 1989;36(3):378–84.
32. Emmerison BT. Alteration of urate metabolism by weight reduction. Aust NZ J Med. 1973;3(4):410–2.
33. Dalbeth N, Phipps-Green A, House ME, Gamble GD, Horne A, Stamp LK, et al. Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout. Arthritis Res Ther. 2015;17:263.
34. Caulfield MJ, Munroe PB, O’Neill D, Witkowska K, Charchar FJ, Doblado M, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5(10):1509–23.
35. Hollis-Moffatt JE, Xu X, Dalbeth N, Merriman ME, Topless R, Waddell C, et al. Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Maori, Pacific Island, and Caucasian case-control sample sets. Arthritis Rheum. 2009;60(11):3485–92.
36. Tanner C, Bocock J, Stahl EA, Dobbyn A, Mandal AK, Cadzow M, et al. Population-specific Resequencing associates the ATP-binding cassette subfamily C member 4 gene with gout in New Zealand Maori and Pacific men. Arthritis Rheum. 2017;69(7):1461–9.
37. Kannangara DR, Phipps-Green AJ, Dalbeth N, Stamp LK, Williams KM, Graham GG, et al. Hyperuricaemic contributions of urate transporter ABCG2 and the fractional renal clearance of urate. Ann Rheum Dis. 2016;75(7):1363–6.
38. Vaxillaire M, Cavalcanti-Proenca C, Dechaume A, Tichet J, Marce M, Balkau B, et al. The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population. Diabetes. 2008;57(8):2253–7.
39. van der Harst P, Bakker SJ, de Boer RA, Wolfenbuttel BH, Johnson T, Caulfield MJ, et al. Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. Hum Mol Genet. 2010;19(2):387–95.
40. Tin A, Li Y, Brody JA, Nuttle T, Chu AY, Huffman JE, et al. Large-scale whole-exome sequencing association studies identify rare functional variants influencing serum urate levels. Nat Commun. 2018;9:4228.
41. Kottgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, Glazer NL, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet. 2010;42(5):376–84.
42. Pattaro C, Teumer A, Gorski M, Chu AY, Li M, Mijatovic V, et al. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nat Commun. 2016;7:10023.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.